BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
Plain-language summary
This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 60 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
BCL-2 inhibitors combined with the HyperCVAD regimen (DRUG): BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL | Propensity score matching historical data (OTHER): Propensity score matching was conducted with historical data (matching factors included age, gender, initial LDH levels, and the presence or absence of a large mediastinal mass at diagnosis) to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols.
- Drugs / treatments
- BCL-2 inhibitors combined with the HyperCVAD regimen, Propensity score matching historical data
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details